Edition:
United States

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

93.87USD
3:59pm EST
Change (% chg)

$0.88 (+0.95%)
Prev Close
$92.99
Open
$93.70
Day's High
$94.66
Day's Low
$92.83
Volume
67,887
Avg. Vol
121,426
52-wk High
$118.71
52-wk Low
$27.94

Select another date:

Mon, Nov 13 2017

BRIEF-Beigene expands global pivotal program for BTK inhibitor BGB-3111

* Beigene expands global pivotal program for BTK inhibitor BGB-3111

BRIEF-Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​

* Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​ Source text for Eikon: Further company coverage:

BRIEF-Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​

* Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​ Source text : (http://bit.ly/2guND0F) Further company coverage:

BRIEF-Beigene prices 2.46 mln ADS at $71 per unit

* Pricing of its follow-on public offering of 2,465,000 american depositary shares at a price to public of $71.00 per ads Source text for Eikon: Further company coverage:

BRIEF-Beigene announces proposed public offering

* Beigene Ltd - ‍announced a public offering of adss each representing 13 of its ordinary shares, par value $0.0001 per share​

Celgene signs deal with BeiGene for tumor cancer treatment

Celgene Corp said it would buy a stake in BeiGene Ltd to help develop and commercialize the China-based cancer immunotherapy developer's treatment for solid tumor cancers, expanding its position in the field of immuno-oncology.

UPDATE 1-Celgene signs deal with BeiGene for tumor cancer treatment

July 6 Celgene Corp said it would buy a stake in BeiGene Ltd to help develop and commercialize the China-based cancer immunotherapy developer's treatment for solid tumor cancers, expanding its position in the field of immuno-oncology.

Celgene to buy BeiGene stake, to develop tumor cancer treatment

July 5 Biopharmaceutical company Celgene Corp will buy a stake in BeiGene Ltd and help develop and commercialize BeiGene's investigational treatment for tumor cancers, the companies said on Wednesday.

BRIEF-Celgene enters collaboration with BeiGene to advance inhibitor program for solid tumor cancers

* Celgene Corporation enters into global strategic immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers

BRIEF-Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China

* Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China in patients with urothelial cancer

Select another date: